Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Endocrinology, Diabetes & Metabolism
Hung-Wei LiaoBruce Ovbiagele

Abstract

To evaluate the efficacy and safety of combined therapy with sodium-glucose cotransporter 2 (SGLT-2) inhibitors plus pioglitazone versus pioglitazone alone in type 2 diabetic patients. Systematic literature searches were performed across PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and clinicaltrials.gov from 1966 to September 2018 to identify randomized, controlled trials. Mean difference (MD) or odds ratio (OR) was used to evaluate efficacy and safety end-points (active group vs control group), wherever appropriate. Heterogeneity was assessed by P value of χ2 statistics and I2. Four randomized controlled trials with 1411 diabetic patients were included. Pooling data from included trials showed that HbA1c change was significantly larger in both low-dose SGLT-2 inhibitors (MD: -0.59%, 95% CI: -0.77 to -0.41%) and high-dose SGLT-2 inhibitors (MD: -0.65%, 95% CI: -0.78 to -0.53%) plus pioglitazone than pioglitazone alone in 24-26 weeks. Favourable outcomes were also found in fasting blood glucose level reduction and more patients achieving HbA1c <7% in SGLT-2 inhibitor plus pioglitazone (OR: 3.21, 95% CI: 1.99 to 5.16). Also, SGLT-2 inhibitor plus pioglitazone vs pioglitazone, reduced weight and blood pressure....Continue Reading

References

Nov 15, 2006·JAMA : the Journal of the American Medical Association·Theodore MazzoneSteven M Haffner
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Apr 2, 2008·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN PERISCOPE Investigators
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Aug 2, 2013·Diabetes Care·Guntram SchernthanerGerit-Holger Schernthaner
Dec 4, 2014·The Lancet. Diabetes & Endocrinology·Anoop Dinesh ShahHarry Hemingway
Dec 31, 2014·Journal of the Chinese Medical Association : JCMA·Chern-En ChiangShing-Jong Lin
May 6, 2015·Therapeutic Advances in Endocrinology and Metabolism·Nasser AghamohammadzadehHamidreza Ahadi
Jul 4, 2015·Clinical Therapeutics·Christopher S KovacsUNKNOWN EMPA-REG EXTEND™ PIO investigators
Jul 25, 2015·Diabetes Care·UNKNOWN International Hypoglycaemia Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 9, 2016·Endocrine·R P Monica Reddy, Silvio E Inzucchi
Dec 22, 2016·Stroke; a Journal of Cerebral Circulation·Meng LeeBruce Ovbiagele
Feb 9, 2017·Frontiers in Endocrinology·Arun ChaudhuryWasique Mirza
Apr 23, 2017·Diabetes, Obesity & Metabolism·Ralph A DeFronzo
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Nov 23, 2017·Diabetology & Metabolic Syndrome·Elena FilipovaToni Vekov
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Mar 13, 2018·Circulation·Karin RådholmBruce Neal

❮ Previous
Next ❯

Software Mentioned

Review Manager Package RevMan

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.